RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841‐985; doi: 10.1177/10507256251363120.
2.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid2016;26:1‐133; doi: 10.1089/thy.2015.0020.
3.
SchlumbergerM, LeboulleuxS, CatargiB, et al.Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol2018;6(8):618‐626; doi: 10.1016/S2213-8587(18)30113-x.
4.
DehbiHM, MallickU, WadsleyJ, et al.Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol2019;7(1):44‐51; doi: 10.1016/S2213-8587(18)30306-1.
5.
LeboulleuxS, BournaudC, ChougnetCN, et al.Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med.2022;386(10):923‐932; doi: 10.1056/NEJMoa2111953.
6.
ChouR, DanaT, BrentGA, et al.Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: A systematic review. Thyroid2022;32(6):613‐639; doi: 10.1089/thy.2021.0666.
7.
HirshorenN, KaganovK, WeinbergerJM, et al.Thyroidectomy practice after implementation of the 2015 American Thyroid Association guidelines on surgical options for patients with well-differentiated thyroid carcinoma. JAMA Otolaryngol Head Neck Surg2018;144(5):427‐432; doi: 10.1001/jamaoto.2018.0042.
8.
KuoLE, AngellTE, PandianTK, et al.Completion thyroidectomy is less common following updated 2015 American Thyroid Association guidelines. Ann Surg Oncol2021;28(1):484‐491; doi: 10.1245/s10434-020-08709-x.
9.
BojogaA, KootA, BonenkampJ, et al.The impact of the extent of surgery on the long-term outcomes of patients with low-risk differentiated non-medullary thyroid cancer: A systematic meta-analysis. J Clin Med2020;9(7):2316; doi: 10.3390/jcm9072316.
10.
GartlandRM, LubitzCC. Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. Ann Surg Oncol2018;25(9):2520‐2525; doi: 10.1245/s10434-018-6550-2.
11.
Rodriguez SchaapPM, BottiM, OttenRHJ, et al.Hemithyroidectomy versus total thyroidectomy for well differentiated T1-2 N0 thyroid cancer: Systematic review and meta-analysis. BJS Open2020;4(6):987‐994; doi: 10.1002/bjs5.50359.
12.
ChanS, KaramaliK, KolodziejczykA, et al.Systematic review of recurrence rate after hemithyroidectomy for low-risk well-differentiated thyroid cancer. Eur Thyroid J2020;9(2):73‐84; doi: 10.1159/000504961.
13.
Vargas-PintoS, Romero ArenasMA. Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: A systematic review. J Surg Res2019;242:244‐251; doi: 10.1016/j.jss.2019.04.036.
14.
ZhangC, LiY, LiJ, et al.Total thyroidectomy versus lobectomy for papillary thyroid cancer: a systematic review and meta-analysis. Medicine (Baltimore)2020;99(6):e19073; doi: 10.1097/MD.0000000000019073.
15.
TuttleM, HaugenB, ShahJ, et al.Thyroid-differentiated and anaplastic carcinoma. In: AJCC Cancer Staging Manual, 8th ed. (AminMB, GreeneF, ByrdDR, eds.) Springer International: New York; 2017.
